3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Uterine Cervical Neoplasms
2
Advanced Solid Tumours
2
Vaginal Neoplasms
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Previously Treated Non Small Cell Lung Cancer
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Endometrioid
1
Blast Crisis
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
3
Carboplatin
3
Nivolumab
2
Injections
2
Docetaxel
2
Cisplatin
2
BMS-753493
2
zimberelimab
1
urelumab
1
tislelizumab
1
tesetaxel
1
spartalizumab
1
olaparib
1
liposomal doxorubicin
1
linifanib
1
lenvatinib
1
ixabepilone
1
durvalumab
1
avelumab
1
avdoralimab
1
adavosertib
1
TAS-119
1
Rifampin
1
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
1
Maximum Tolerated Dose
1
Linoleic Acids, Conjugated
1
Lapatinib
1
Itraconazole
1
Irinotecan
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Solid Tumors
×
adavosertib
×
Clear all
NCT05008913
2022-09-06
ADME
AstraZeneca
Phase 1
Terminated
2 enrolled